When Content Is Cheap, Review Becomes the Bottleneck in Pharma Marketing

A panelist at Fierce Pharma’s September 2026 session described a content hub, called Mosaic, that drives significant cost efficiency, particularly for US content production. It also supplies the variation volume that personalization at scale needs. The same panel noted that synthetic personas built from market research are speeding up how brand teams synthesize insight, and that brand teams spend hours every other week in a room trying to make sense of research and data.

Then came a telling aside. If marketers can now generate content on their own desktops, where does a centralized content hub fit? The panelist raised it as an open question the organization needs to think through. (Part three of five from the panel. Earlier: personalization to n=1 and AI suggestions field teams act on.)

The new constraint

When creation gets cheap, the queue moves downstream. An IQVIA blog post from July 2026 makes the same point from the review side: AI makes it fast to produce many content variants, so the bottleneck shifts from creation to review and approval, and many medical, legal and regulatory (MLR) review models were built for lower volumes and more predictable campaigns. The author is a vendor that sells MLR-related services, so the framing favors its offerings, and the post offers no quantitative data. The structural observation still holds.

What can be automated, and what can’t

The post describes agentic AI as able to check content against approved claims, verify references, flag potential compliance issues, find inconsistencies across materials and manage workflow. It argues humans should keep interpretation, country-specific regulatory differences, scientific nuance and final accountability. It cites UK PMCPA guidance that AI may support compliance but doesn’t remove a company’s responsibilities under the ABPI Code, and that final certification by a nominated signatory can’t be met by AI alone.

That split, AI for volume and humans for judgment, is the same one I’d recommend for any team using AI to grade AI (more in who grades the grader?).

Where AI review fails

The post lists a few predictable ways this goes wrong:

• Automating an inefficient process, which just scales the inefficiency.
• Reference libraries with duplicates, outdated materials and weak traceability.
• Claims libraries that don’t match current campaigns or link back to evidence.
• Unclear ownership of AI outputs and unclear permission for AI use.

A practical sequence

1. Fix the claims and reference library first. Link every claim to its evidence in a format AI can read.
2. Define where human review is mandatory and who owns the decision.
3. Let AI do first-pass checks on claims, references and consistency, with humans on judgment calls. The RISE eval structure is a reasonable template for those checks.
4. Pilot before scaling, and update SOPs and training as you go.

This connects to the panel’s wider theme, which is tomorrow’s post: the tools are ready faster than the organization is. If personalization depends on variant volume, then MLR capacity, not generation capacity, sets your ceiling.

Scaling AI content in a regulated industry? Get in touch.